Lancet Neurology

Article	Citations
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	2422
Neurological associations of COVID-19	1450
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series	944
Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?	747
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts	673
Challenges in the diagnosis of Parkinson's disease	506
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches	417
Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches	411
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group	408
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation	376
Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues	315
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis	313
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria	285
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial	275
Myelin-oligodendrocyte glycoprotein antibody-associated disease	268
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias	264
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial	233
New insights into atypical Alzheimer's disease in the era of biomarkers	230
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study	230
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study	223
Traumatic brain injury: progress and challenges in prevention, clinical care, and research	219
Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia	211
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial	206
Remyelination in multiple sclerosis: from basic science to clinical translation	194
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	186

Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial	182
Seizure outcome and use of antiepileptic drugs after epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study	181
Long-term unsupervised mobility assessment in movement disorders	181
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study	178
The influence of timing of surgical decompression for acute spinal cord injury: a pooled analysis of individual patient data	176
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study	163
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-cont	162
A case of probable Parkinson's disease after SARS-CoV-2 infection	161
Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease	157
An Italian programme for COVID-19 infection in multiple sclerosis	157
Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation	152
The neuropsychiatry of Parkinson's disease: advances and challenges	148
Progress towards therapies for disease modification in Parkinson's disease	145
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis	141
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials	140
30 years of second-generation antiseizure medications: impact and future perspectives	139
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial	137
Monogenic variants in dystonia: an exome-wide sequencing study	136
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	133
Multiple sclerosis progression: time for a new mechanism-driven framework	131
Functional neurological disorder: new subtypes and shared mechanisms	127
Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts	125
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial	122
Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis	120
PET imaging of neuroinflammation in neurological disorders	120
Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial	120
Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder	119
Post-viral effects of COVID-19 in the olfactory system and their implications	119
Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU): an international, prospective observational cohort study	118
Neuroimaging standards for research into small vessel disease—advances since 2013	116
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial	116
Neuromodulation in epilepsy: state-of-the-art approved therapies	115
COVID-19 related stroke in young individuals	114
Evidence-based support for autistic people across the lifespan: maximising potential, minimising barriers, and optimising the person–environment fit	113
Moyamoya disease: diagnosis and interventions	113
Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised contr	112
Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial	110
Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study	110
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how	109
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities	108
Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care	106
Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies	103
Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis	103
Alzheimer's disease associated with Down syndrome: a genetic form of dementia	103
Forecasting seizure risk in adults with focal epilepsy: a development and validation study	102
Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies	102
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled,	100
Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances	99
Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective	97
Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment	97

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial	96
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study	96
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial	96
Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study	96
SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy	95
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial	94
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials	94
Brain injury after cardiac arrest: from prognostication of comatose patients to rehabilitation	91
Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial	91
Ageing without dementia: can stimulating psychosocial and lifestyle experiences make a difference?	90
Mitochondrial disease in adults: recent advances and future promise	89
Prevalence, predictors, and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke: a population-based cohort study	87
Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled st	87
Clinical characteristics and outcomes in patients with traumatic brain injury in China: a prospective, multicentre, longitudinal, observational study	86
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial	86
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial	86
Cell-based and stem-cell-based treatments for spinal cord injury: evidence from clinical trials	86
Epilepsy in China: major progress in the past two decades	85
New therapies for neuromyelitis optica spectrum disorder	85
A biological classification of Huntington's disease: the Integrated Staging System	83
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)	81
Diagnosis and classification of optic neuritis	80
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders	80
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study	79
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial	76
Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study	76
Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches	76
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial	71
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations	71
Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial	71
Amantadine in the treatment of Parkinson's disease and other movement disorders	71
Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study	69
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial	69
Menstrual migraine: a distinct disorder needing greater recognition	68
Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial	68
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	66
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial	64
Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions	64
Global prevention of stroke and dementia: the WSO Declaration	63
Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments	62
Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study	62
Sleep disorders in autoimmune encephalitis	62
Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment	59
Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care	59
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, pha	57
Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohor	57
Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies	57
Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study	55
The role of manganese dysregulation in neurological disease: emerging evidence	54
Spontaneous intracranial hypotension: searching for the CSF leak	54
Sleep function: an evolutionary perspective	54
Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment	53
Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study	52
Ageing and multiple sclerosis	52
Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study	52
Dreams and nightmares in healthy adults and in patients with sleep and neurological disorders	52
Diagnosis and treatment of orthostatic hypotension	52
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, pl	51
Prehospital stroke management in the thrombectomy era	51
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study	50
Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours	50
Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial	50
Thrombolysis for acute ischaemic stroke: current status and future perspectives	50
Antipsychotic prescribing to people with dementia during COVID-19	50
Casemix, management, and mortality of patients receiving emergency neurosurgery for traumatic brain injury in the Global Neurotrauma Outcomes Study: a prospective observational cohort study	50
Cognitive-motor dissociation and time to functional recovery in patients with acute brain injury in the USA: a prospective observational cohort study	49
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	49
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study	49
Management of atherosclerotic extracranial carotid artery stenosis	49
Long COVID: understanding the neurological effects	48
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 tri	48
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase	48
CDKL5 deficiency disorder: clinical features, diagnosis, and management	47
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phas	47
Potential human transmission of amyloid β pathology: surveillance and risks	46
Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial	45
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study	45
Sleep apnoea and ischaemic stroke: current knowledge and future directions	44
Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 tr	44
Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study	44

Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial	43
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders	43
Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies	43
COVID-19 and selective vulnerability to Parkinson's disease	43
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial	42
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	42
Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme	41
Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study	41
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial	41
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial	41
Emerging therapies for Duchenne muscular dystrophy	40
Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders	40
Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack:	40
Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial	39
Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study	39
Intraoperative electrocorticography using high-frequency oscillations or spikes to tailor epilepsy surgery in the Netherlands (the HFO trial): a randomised, single-blind, adaptive non-inferiority tria	39
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	38
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study	38
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial	37
Tuberculous meningitis: progress and remaining questions	37
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial	37
Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development	36
Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission	36
Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy	35
Intracerebral haemorrhage expansion: definitions, predictors, and prevention	34
Sleep research in 2020: COVID-19-related sleep disorders	34
Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study	34
Informed consent procedures for emergency interventional research in patients with traumatic brain injury and ischaemic stroke	34
Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy	34
Effect of frailty on 6-month outcome after traumatic brain injury: a multicentre cohort study with external validation	34
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	33
Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crosso	32
Parkinson's disease outside the brain: targeting the autonomic nervous system	32
Personalised virtual brain models in epilepsy	32
Drug resistance in epilepsy	31
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial	31
Research priorities to improve stroke outcomes	31
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	30
Traumatic brain injury as a chronic disease: insights from the United States Traumatic Brain Injury Model Systems Research Program	30
Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study	29
BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study	29
Progression of cerebral amyloid angiopathy: a pathophysiological framework	29
The role of diet in secondary stroke prevention	29
Surgery versus conservative treatment for traumatic acute subdural haematoma: a prospective, multicentre, observational, comparative effectiveness study	28
Genetics of multiple sclerosis: lessons from polygenicity	28
Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China	28
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	27
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	27
Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management	27
Guillain-Barré syndrome after vaccination against COVID-19	27
Heart health meets cognitive health: evidence on the role of blood pressure	27
Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study	27
NeuroCOVID: it's time to join forces globally	26
Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group,	26
Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-con	26
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria	25
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial	25
Lifestyle factors and migraine	25
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research	24
Family planning considerations in people with multiple sclerosis	24
Advances in Alzheimer's disease research over the past two decades	24
The neurological impact of COVID-19	23
Imaging of the optic nerve: technological advances and future prospects	23
Tourette syndrome: clinical features, pathophysiology, and treatment	22
A call for a global COVID-19 Neuro Research Coalition	22
COVID-19 in older people with cognitive impairment in Latin America	22
A new definition of brain health	22
Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study	22
Social media could address the gender gap in neurosurgery	21
Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial	21
Towards understanding the effects of spaceflight on the brain	20
The necessity of diplomacy in brain health	20
Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease	20
Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3	20
Wearable-based mobility monitoring: the long road ahead	19
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial	18
Freezing of gait before the introduction of levodopa	18
Multiple sclerosis under the spotlight	18
Differential diagnosis of suspected multiple sclerosis: an updated consensus approach	18
COVID-19: can we learn from encephalitis lethargica?	17
Multiple sclerosis: two decades of progress	17
New hope for advancing neuropalliative care	17
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	17
Carpal tunnel syndrome: updated evidence and new questions	17
WHO launches its Global Action Plan for brain health	17
The mechanisms of smell loss after SARS-CoV-2 infection	16
Off-label use of aducanumab for cerebral amyloid angiopathy	16
Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	16
Brain network reorganisation in an adolescent after bilateral perinatal strokes	16
BTK inhibitors as potential therapies for multiple sclerosis	15
Movement disorders research in 2021: cracking the paradigm	15
Traumatic brain injury over the past 20 years: research and clinical progress	15
The relevance of social and commercial determinants for neurological health	15
Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial	15
Prion biology: implications for Alzheimer's disease therapeutics	15